Pharmaceutical Representative - Home Page
Tuesday, Feb 9, 2010
Search

ADVERTISEMENT

Previous StoryPlay / PauseNext Story
Featured News
Congress Ups the Pharma Ante for Health Reform
House bill boosts rebates and opens the door to government price negotiations.
FDA Warning Letters Target Illegal Online Pharmacies
Feds targeted 136 Web sites offering foreign or unapproved drugs as part of International Internet Week of Action. But does the FDA campaign ignore a larger crisis endangering consumers?
Online H1N1 self-assessment tool launched
Microsoft has launched a new Web site, www.h1n1responsecenter.com, with a self-assessment tool to help individuals with flu-like symptoms determine whether their illness is severe enough to warrant immediate medical attention, and whether they are at risk for developing severe disease. The site also offers practical advice for those with flu-like symptoms.
Abbott to Pay $1.67B in Patent Suit
J&J emerged victorious in a patent suit claiming that the technology behind Abbott's blockbuster arthritis treatment Humira is too similar in design to J&J's Remicade. The cost to Abbott: $1.67 Billion.
Industry, Health Agencies Respond to Influenza Pandemic
Following the World Health Organization's declaration last week of an influenza pandemic, vaccine makers in Europe and China as well as world health agencies are stepping up efforts toward rapid development and approval of an effective vaccine.
Sudden Deaths and ADHD Meds Not Necessarily Related
Feds claim results of study comparing car crash deaths and children on ADHD drugs were not paramount to pulling kids off of ADHD treatments.
GSK battles with Russian government
The Russian government wants the drug maker to discount its current pricing by 15%, but GSK is balking at the demand
Abbott Medical Optics halts future production of 3% sodium hyaluronate
Abbott Medical Optics said it has decided to halt future production of its newest ophthalmic viscosurgical device, 3% sodium hyaluronate (Healon D), citing concerns about the company's ability to ensure a continuous supply to the market.
Survey
The more people talk about healthcare reform the less consensus there is, what do you think of current efforts to reform the system?
Healthcare reform is
Good for pharma
Bad for pharma
Doomed to failure
An idea whose time has come
Good for pharma
19%
Bad for pharma
38%
Doomed to failure
24%
An idea whose time has come
19%
GOOGLE ADVERTISEMENTS
FindPharma
Click here